Francesco Fausto Palazzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francesco Fausto Palazzo has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Aimee N. Di Marco
Department of Endocrine Surgery Imperial College Healthcare NHS Trust Hammersmith Hospital London London UK
8 shared publications - Ioannis Christakis
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publications Karim Meeran
Department of Medicine, Imperial College, London, United Kingdom
3 shared publications- Neil S. Tolley
Department of Endocrine & Thyroid Surgery, Hammersmith Hospital, London, UK
3 shared publications Amir H. Sam
Division of Diabetes, Endocrinology and Metabolism Hammersmith Hospital Imperial College London London, UK
2 shared publicationsIoannis Christakis
Department of Endocrine and General Surgery, Kings' College Hospital, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by IMR Press in British Journal of Hospital Medicine
- Vol. 87 (9)
Parathyroid Surgery for Primary Hyperparathyroidism in 2026
Primary hyperparathyroidism (PHPT) is the most common parathyroid disease and one of the most common endocrine disorders. It results from autonomous overproduction of parathyroid hormone, which in the classic form of the disease causes hypercalcaemia. The ready access to biochemical testing in high-income countries has moved the disease spectrum from a classic symptomatic presentation to a biochemical anomaly that is asymptomatic or minimally symptomatic. Untreated PHPT, however, remains associated with significant consequences. This review summarizes up-to-date concepts in the diagnosis, imaging, and surgical management of PHPT. The diagnosis of PHPT requires confirmation of hypercalcaemia with inappropriately elevated or unsuppressed parathyroid hormone levels, while excluding alternative causes. Parathyroidectomy remains the only definitive cure for PHPT, and the changing thresholds for intervention are discussed. Advances in pre-operative localization, including high-resolution ultrasonography, 99mTc-sestamibi (technetium-99m methoxyisobutylisonitrile), 4D-computed tomography, and fluorocholine positron emission tomography, have increased the number of patients with localised disease and therefore facilitated focused and minimally invasive surgical approaches. Intraoperative parathyroid hormone monitoring has also added a new dimension to intraoperative decision-making. However, the single biggest determinant of outcome in parathyroidectomy remains the practice volume and experience of the operating surgeon. It remains to be seen whether emerging technologies, including robotic surgery, thermal ablation, advanced molecular imaging, and artificial intelligence–assisted diagnosis and lesion localization, will further refine patient selection and improve treatment strategies in PHPT.
- 10 September 2026
- Published by IMR Press in British Journal of Hospital Medicine
- Vol. 87 (9)
Open AccessParathyroid Surgery for Primary Hyperparathyroidism in 2026
Primary hyperparathyroidism (PHPT) is the most common parathyroid disease and one of the most common endocrine disorders. It results from autonomous overproduction of parathyroid hormone, which in the classic form of the disease causes hypercalcaemia. The ready access to biochemical testing in high-income countries has moved the disease spectrum from a classic symptomatic presentation to a biochemical anomaly that is asymptomatic or minimally symptomatic. Untreated PHPT, however, remains associated with significant consequences. This review summarizes up-to-date concepts in the diagnosis, imaging, and surgical management of PHPT. The diagnosis of PHPT requires confirmation of hypercalcaemia with inappropriately elevated or unsuppressed parathyroid hormone levels, while excluding alternative causes. Parathyroidectomy remains the only definitive cure for PHPT, and the changing thresholds for intervention are discussed. Advances in pre-operative localization, including high-resolution ultrasonography, 99mTc-sestamibi (technetium-99m methoxyisobutylisonitrile), 4D-computed tomography, and fluorocholine positron emission tomography, have increased the number of patients with localised disease and therefore facilitated focused and minimally invasive surgical approaches. Intraoperative parathyroid hormone monitoring has also added a new dimension to intraoperative decision-making. However, the single biggest determinant of outcome in parathyroidectomy remains the practice volume and experience of the operating surgeon. It remains to be seen whether emerging technologies, including robotic surgery, thermal ablation, advanced molecular imaging, and artificial intelligence–assisted diagnosis and lesion localization, will further refine patient selection and improve treatment strategies in PHPT.
- Open Access
- 31 October 2024
- Published by Wiley in World Journal of Surgery
- Vol. 49 (1) , 138-139
Invited commentary: Lymph node yield independently predicts local recurrence in papillary thyroid cancer
- 31 October 2024
- Published by Wiley in World Journal of Surgery
- Vol. 49 (1) , 138-139
Open AccessInvited commentary: Lymph node yield independently predicts local recurrence in papillary thyroid cancer
- 6 June 2024
- Published by Springer Nature
- p. 519-524
Bilateral Exploration Parathyroidectomy
- 31 October 2023
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 94
Management of thyroid nodules in patient with phosphatase and tensin homolog gene (PTEN) mutation
Introduction: Phosphatase and tensin homolog gene (PTEN) gene encodes a lipid phosphatase that plays a central role in cell-cycle processes. PTEN hamartoma tumour syndrome (PHTS), caused by the mutation of the PTEN gene, is a diverse multi-system disorder. PHTS is characterised by the hamartomatous growths, increased risk of breast, thyroid, and renal cancers. In terms of thyroid presentation of PHTS, there is up to 75% risk of multinodular goitre and the lifetime risk for the thyroid cancer is around 1 in 3. Papillary pathology is more common than follicular. Management pathways for the PHTS related thyroid nodules remain unclear. Methods: We studied 10 patients with PHTS from the Imperial College London Endocrinology Clinic. The PHTS-related thyroid involvement was summarised. We focused on the thyroid nodule presentation, treatment, and surveillance. Results: Of the recruited 10 patients, half of them were female with average age of 45. 1 patient had hypothyroidism at the time of the diagnosis. 9 patients showed thyroid changes on ultrasound scan (7 benign multinodular goitre, 1 autoimmune thyroiditis and 1 follicular thyroid carcinoma) and 3 of them received fine needle aspiration cytology (FNAC) for U3 nodules on the scan. 5 patients received partial/total thyroidectomy. Patients without thyroidectomy are receiving annual ultrasound surveillance. Other organ involvement included: macrocephaly 5 cases, lipoma 4 cases, colon polyps/adenomas 5 cases, breast nodules 4 cases and renal cysts/tumours 2 cases. Conclusion: We followed the current guideline of annual thyroid ultrasounds starting at the time of PHTS diagnosis. However, whether these patients should have thyroid FNA is controversial, as follicular lesions can be difficult to distinguish via FNA. A more proactive approach to thyroidectomy may be required, considering the lifetime risk of thyroid cancer in PTHS patients.
- 31 October 2023
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 94
Management of thyroid nodules in patient with phosphatase and tensin homolog gene (PTEN) mutation
Introduction: Phosphatase and tensin homolog gene (PTEN) gene encodes a lipid phosphatase that plays a central role in cell-cycle processes. PTEN hamartoma tumour syndrome (PHTS), caused by the mutation of the PTEN gene, is a diverse multi-system disorder. PHTS is characterised by the hamartomatous growths, increased risk of breast, thyroid, and renal cancers. In terms of thyroid presentation of PHTS, there is up to 75% risk of multinodular goitre and the lifetime risk for the thyroid cancer is around 1 in 3. Papillary pathology is more common than follicular. Management pathways for the PHTS related thyroid nodules remain unclear. Methods: We studied 10 patients with PHTS from the Imperial College London Endocrinology Clinic. The PHTS-related thyroid involvement was summarised. We focused on the thyroid nodule presentation, treatment, and surveillance. Results: Of the recruited 10 patients, half of them were female with average age of 45. 1 patient had hypothyroidism at the time of the diagnosis. 9 patients showed thyroid changes on ultrasound scan (7 benign multinodular goitre, 1 autoimmune thyroiditis and 1 follicular thyroid carcinoma) and 3 of them received fine needle aspiration cytology (FNAC) for U3 nodules on the scan. 5 patients received partial/total thyroidectomy. Patients without thyroidectomy are receiving annual ultrasound surveillance. Other organ involvement included: macrocephaly 5 cases, lipoma 4 cases, colon polyps/adenomas 5 cases, breast nodules 4 cases and renal cysts/tumours 2 cases. Conclusion: We followed the current guideline of annual thyroid ultrasounds starting at the time of PHTS diagnosis. However, whether these patients should have thyroid FNA is controversial, as follicular lesions can be difficult to distinguish via FNA. A more proactive approach to thyroidectomy may be required, considering the lifetime risk of thyroid cancer in PTHS patients.
- Open Access
- 18 September 2023
- Published by Springer Nature
- p. 71-81
Cervical Lymphadenectomy in Papillary Thyroid Cancer
- 18 September 2023
- Published by Springer Nature
- p. 71-81
Open AccessCervical Lymphadenectomy in Papillary Thyroid Cancer
- Open Access
- 1 July 2023
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 1 (4) , luad077
Emerging Potential of Microwave Ablation for Primary Aldosteronism Resulting From Unilateral Aldosterone-producing Adenoma
Primary aldosteronism (PA) is the most prevalent form of secondary hypertension and is most commonly caused by an adrenal adenoma or bilateral adrenal hyperplasia. Minimally invasive adrenalectomy is the treatment of choice for unilateral disease. Here, we report the case of a 57-year-old man with previous bladder cancer who was referred for evaluation of resistant hypertension and hypokalemia. Diagnostic workup indicated PA with computed tomography imaging revealing a left adrenal adenoma and adrenal venous sampling lateralizing to the left adrenal. He was therefore referred for a left adrenalectomy using a retroperitoneoscopic approach. However, surgery was complicated by significant perinephritis related to previous bladder cancer immunotherapy and, in view of an identifiable adrenal adenoma, a partial adrenalectomy was performed. Despite histology confirming removal of an adrenal adenoma, he remained hypertensive and hypokalemic with persistent PA. He underwent a computed tomography-guided percutaneous thermal (microwave) ablation of the residual adrenal nodule with immediate biochemical reversal of PA. Six years postprocedure, he remains biochemically and clinically cured from PA. This article presents the details of the case and reviews the literature on long-term outcomes for patients undergoing thermal ablation and adrenalectomy, suggesting that thermal ablation may be a viable alternative for selected patients.
- 1 July 2023
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 1 (4) , luad077
Open AccessEmerging Potential of Microwave Ablation for Primary Aldosteronism Resulting From Unilateral Aldosterone-producing Adenoma
Primary aldosteronism (PA) is the most prevalent form of secondary hypertension and is most commonly caused by an adrenal adenoma or bilateral adrenal hyperplasia. Minimally invasive adrenalectomy is the treatment of choice for unilateral disease. Here, we report the case of a 57-year-old man with previous bladder cancer who was referred for evaluation of resistant hypertension and hypokalemia. Diagnostic workup indicated PA with computed tomography imaging revealing a left adrenal adenoma and adrenal venous sampling lateralizing to the left adrenal. He was therefore referred for a left adrenalectomy using a retroperitoneoscopic approach. However, surgery was complicated by significant perinephritis related to previous bladder cancer immunotherapy and, in view of an identifiable adrenal adenoma, a partial adrenalectomy was performed. Despite histology confirming removal of an adrenal adenoma, he remained hypertensive and hypokalemic with persistent PA. He underwent a computed tomography-guided percutaneous thermal (microwave) ablation of the residual adrenal nodule with immediate biochemical reversal of PA. Six years postprocedure, he remains biochemically and clinically cured from PA. This article presents the details of the case and reviews the literature on long-term outcomes for patients undergoing thermal ablation and adrenalectomy, suggesting that thermal ablation may be a viable alternative for selected patients.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Delta-like non-canonical Notch ligand 1 (DLK1) - a novel biomarker in adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options and a heterogenous prognosis. The histological diagnosis of ACC is complex and there is increasing interest in identifying and validating new immunohistochemical markers. Delta-like non-canonical Notch ligand 1 (DLK1) is a cleavable single-pass transmembrane protein. In humans, DLK1 is present in many tissues during foetal development, is restricted to progenitor/stem cells in a few adult tissues but is expressed in numerous malignancies. We have previously shown that DLK1 is overexpressed in ACC compared to normal adrenal gland and aldosterone producing adenomas. In a validation cohort of 196 ACC tumour samples (149 primary, 47 secondary), we have found that DLK1 is expressed in 96% of samples. Level of expression is independent of ENSAT stage, Ki67 index or hormonal activity of the tumour and consistent in primary and secondary disease in the same patients (P=0.034). Additionally, higher levels of DLK1 expression (above vs below median) are associated with a two-fold increased risk of disease recurrence after surgery (HR 1.93, P=0.042). Furthermore, we have found that serum DLK1 levels are detectable in patients with ACC and in an initial cohort are significantly higher in patients with ACC (mean=20.41ng/ml, n=8) than patients undergoing adrenalectomy for other suspected adrenocortical pathologies (mean=13.14ng/ml, n=27; P=0.0003). Pre-operative DLK1 serum levels can predict the diagnosis of ACC with a high level of specificity and sensitivity (ROC AUC = 0.8796; CI 0.7590 – 1.000, P=0.0013). Finally, raised serum DLK1 levels in ACC patients are significantly reduced post-operatively (17.55 to 10.77ng/ml, n=4; P=0.0123). Our data suggest that DLK1 expression is a disease defining event in ACC that may have a pathological role. In addition, DLK1 serum levels, in combination with immunohistochemical expression in tumours, may provide a clinically useful novel biomarker for the diagnosis and monitoring of ACC.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Delta-like non-canonical Notch ligand 1 (DLK1) - a novel biomarker in adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options and a heterogenous prognosis. The histological diagnosis of ACC is complex and there is increasing interest in identifying and validating new immunohistochemical markers. Delta-like non-canonical Notch ligand 1 (DLK1) is a cleavable single-pass transmembrane protein. In humans, DLK1 is present in many tissues during foetal development, is restricted to progenitor/stem cells in a few adult tissues but is expressed in numerous malignancies. We have previously shown that DLK1 is overexpressed in ACC compared to normal adrenal gland and aldosterone producing adenomas. In a validation cohort of 196 ACC tumour samples (149 primary, 47 secondary), we have found that DLK1 is expressed in 96% of samples. Level of expression is independent of ENSAT stage, Ki67 index or hormonal activity of the tumour and consistent in primary and secondary disease in the same patients (P=0.034). Additionally, higher levels of DLK1 expression (above vs below median) are associated with a two-fold increased risk of disease recurrence after surgery (HR 1.93, P=0.042). Furthermore, we have found that serum DLK1 levels are detectable in patients with ACC and in an initial cohort are significantly higher in patients with ACC (mean=20.41ng/ml, n=8) than patients undergoing adrenalectomy for other suspected adrenocortical pathologies (mean=13.14ng/ml, n=27; P=0.0003). Pre-operative DLK1 serum levels can predict the diagnosis of ACC with a high level of specificity and sensitivity (ROC AUC = 0.8796; CI 0.7590 – 1.000, P=0.0013). Finally, raised serum DLK1 levels in ACC patients are significantly reduced post-operatively (17.55 to 10.77ng/ml, n=4; P=0.0123). Our data suggest that DLK1 expression is a disease defining event in ACC that may have a pathological role. In addition, DLK1 serum levels, in combination with immunohistochemical expression in tumours, may provide a clinically useful novel biomarker for the diagnosis and monitoring of ACC.
- Open Access
- 30 August 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46 (11) , 2676-2677
Invited Commentary: Less than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta‐Analysis
- 30 August 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46 (11) , 2676-2677
Open AccessInvited Commentary: Less than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta‐Analysis
- 13 October 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (3) , e1242-e1248
Correlation of Preoperative Imaging Findings and Parathyroidectomy Outcomes Support NICE 2019 Guidance
Context: Preoperative localization studies are standard practice in patients undergoing parathyroidectomy for primary hyperparathyroidism (pHPT). The most common modalities are neck ultrasound (US) and sestamibi scanning. However, the nature of pHPT is changing, with imaging increasingly yielding negative results. Numerous studies suggest unlocalized disease is associated with poor outcomes, calling into question whether such patients are best treated conservatively. Objective: This study aims to correlate parathyroidectomy outcomes with preoperative imaging in a single, high-volume institution. Methods: Data from a prospectively maintained departmental database of operations performed from 2017 to 2019 were analyzed. All patients undergoing first-time surgery for sporadic pHPT were included. Data collected included patient demographics, preoperative imaging, surgical strategy, and postoperative outcomes. Results: A total of 609 consecutive parathyroidectomies were included, with a median age of 59 years (range 20-87 years). The all-comer cure rate was 97.5%; this was 97.9% in dual localized patients (those with positive US and sestamibi), compared to 95.8% in the dual unlocalized group (those with negative US and sestamibi) (P = 0.33). Unilateral neck exploration was the chosen approach in 59.9% of patients with double-positive imaging and 5.7% of patients with double-negative imaging (otherwise, bilateral parathyroid visualization was performed). There was no significant difference in postoperative complications between patients undergoing unilateral or bilateral neck exploration. Conclusions: Patients with negative preoperative imaging who undergo parathyroidectomy are cured in almost 96% of cases, compared to 98% when the disease is localized. This difference does not reach statistical or clinical significance. These findings therefore support current recommendations that all patients with pHPT who are likely to benefit from operative intervention should be considered for parathyroidectomy, irrespective of preoperative imaging findings.
- 13 October 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (3) , e1242-e1248
Correlation of Preoperative Imaging Findings and Parathyroidectomy Outcomes Support NICE 2019 Guidance
Context: Preoperative localization studies are standard practice in patients undergoing parathyroidectomy for primary hyperparathyroidism (pHPT). The most common modalities are neck ultrasound (US) and sestamibi scanning. However, the nature of pHPT is changing, with imaging increasingly yielding negative results. Numerous studies suggest unlocalized disease is associated with poor outcomes, calling into question whether such patients are best treated conservatively. Objective: This study aims to correlate parathyroidectomy outcomes with preoperative imaging in a single, high-volume institution. Methods: Data from a prospectively maintained departmental database of operations performed from 2017 to 2019 were analyzed. All patients undergoing first-time surgery for sporadic pHPT were included. Data collected included patient demographics, preoperative imaging, surgical strategy, and postoperative outcomes. Results: A total of 609 consecutive parathyroidectomies were included, with a median age of 59 years (range 20-87 years). The all-comer cure rate was 97.5%; this was 97.9% in dual localized patients (those with positive US and sestamibi), compared to 95.8% in the dual unlocalized group (those with negative US and sestamibi) (P = 0.33). Unilateral neck exploration was the chosen approach in 59.9% of patients with double-positive imaging and 5.7% of patients with double-negative imaging (otherwise, bilateral parathyroid visualization was performed). There was no significant difference in postoperative complications between patients undergoing unilateral or bilateral neck exploration. Conclusions: Patients with negative preoperative imaging who undergo parathyroidectomy are cured in almost 96% of cases, compared to 98% when the disease is localized. This difference does not reach statistical or clinical significance. These findings therefore support current recommendations that all patients with pHPT who are likely to benefit from operative intervention should be considered for parathyroidectomy, irrespective of preoperative imaging findings.
- Open Access
Differentiated Thyroid Cancer: A Health Economic Review
The incidence of differentiated thyroid cancer (DTC) is rising, mainly because of an increased detection of asymptomatic thyroid nodularity revealed by the liberal use of thyroid ultrasound. This review aims to reflect on the health economic considerations associated with the increasing diagnosis and treatment of DTC. Overdiagnosis and the resulting overtreatment have led to more surgical procedures, increasing health care and patients’ costs, and a large pool of community-dwelling thyroid cancer follow-up patients. Additionally, the cost of thyroid surgery seems to increase year on year even when inflation is taken into account. The increased healthcare costs and spending have placed significant pressure to identify potential factors associated with these increased costs. Some truly ground-breaking work in health economics has been undertaken, but more cost-effectiveness studies and micro-cost analyses are required to evaluate expenses and guide future solutions.
Open AccessDifferentiated Thyroid Cancer: A Health Economic Review
The incidence of differentiated thyroid cancer (DTC) is rising, mainly because of an increased detection of asymptomatic thyroid nodularity revealed by the liberal use of thyroid ultrasound. This review aims to reflect on the health economic considerations associated with the increasing diagnosis and treatment of DTC. Overdiagnosis and the resulting overtreatment have led to more surgical procedures, increasing health care and patients’ costs, and a large pool of community-dwelling thyroid cancer follow-up patients. Additionally, the cost of thyroid surgery seems to increase year on year even when inflation is taken into account. The increased healthcare costs and spending have placed significant pressure to identify potential factors associated with these increased costs. Some truly ground-breaking work in health economics has been undertaken, but more cost-effectiveness studies and micro-cost analyses are required to evaluate expenses and guide future solutions.